In the first 10 months of 2024, Russian citizens have spent 5.9 billion rubles on generic versions of Ozempic (semaglutide), according to Vedomosti and data from DSM Group. During this time, more than 1 million packages of domestic analogues from Geropharm and Promomed were sold.
Ozempic, the original drug, has not been officially available in Russia since December of last year. The Russian government has permitted local companies to produce semaglutide analogues, bypassing its patent, due to its classification as a vital drug and its absence threatening public health.
For drugs in this group, the sales figure for 10 months of this year was a record since Ozempic entered the Russian market in 2020. For comparison: in January – October 2023, Russian pharmacies earned 297 million rubles. 20,174 packs of ozempic were sold, according to DSM Group data. For the same period in 2022, consumers spent 1.9 billion (256,493 packs were sold), 2021 – 758 million rubles, 2020 – 76 million rubles.
